Politiparty
Politiparty

118th Congress Health

H.R. 7248: FDA Modernization Act 3.0

Introduced

  1. Introduced (completed)Feb 6, 2024
  2. Passed House (not reached)
  3. Passed Senate (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in House, Feb 6, 2024

This bill requires the Food and Drug Administration (FDA) to establish a process that supports nonclinical testing methods for drug development that do not involve the use of animals.

Specifically, the FDA must establish a pathway by which entities may apply to have nonclinical testing methods approved for use in a particular context. Qualifying methods must be intended to replace or reduce animal testing and to either improve the safety and efficacy of nonclinical testing or reduce the time to develop a drug. The FDA must issue its decision within 180 days of receiving an application. The FDA must also prioritize the review of applications for drugs that are developed using an approved nonclinical testing method.

The FDA must annually post a report on its website that summarizes the results of the bill's implementation, including the number of applications received, types of methods that were approved, and the estimated number of animals saved as result of these methods.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

46

Bipartisan support.

Who scored on this bill

12 points earned
  1. 1Earl Carter R-GA SponsorDrew cross-party cosponsors, introduced, reached a cosponsor milestone3 events+12
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Earl Carter

History

  1. Feb 6, 2024Introduced in the House by Earl Carter.
Show the full action history (3 actions)
  1. Feb 9, 2024Referred to the Subcommittee on Health.
  2. Feb 6, 2024Introduced in House
  3. Feb 6, 2024Referred to the House Committee on Energy and Commerce.